Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiplatelet therapy for primary prevention of cardiovascular disease in high-risk COPD patients
2014-005475-86Phase 2Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- May 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of aspirin and ticagrelor in cardiac morbidity, coronary arteriosclerosis and myocardial infarction (MI) (3 arms), sponsored by Newcastle Hospitals NHS Foundation Trust. Primary endpoint: Inhibition of ADP-induced platelet aggregation at 6 months. Started May 2015; status: completed.
02
Drugs
aspirinticagrelor
03
Conditions
cardiac morbiditycoronary arteriosclerosismyocardial infarction (MI)
Beyond the preview
Go deeper on 2014-005475-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005475-86.